TheraCryf PLC (TCF)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.20p

Buy

0.27p

arrow-up0.00p (+0.00%)

Evgen Pharma PLC is a clinical stage drug development company focused on cancer and neurological disease. Its pipeline is based on Sulforadex technology which includes synthetic and stabilized analogues of sulforaphane.
Prices updated at 15 May 2025, 11:18 BST
| Prices minimum 15 mins delay
|
Prices in GBX
FTSE All-Share
arrow-up0.5%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Share price chart

Created with Highcharts 7.2.2202020212022202320242025-5051015
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.